July 9, 2019
Dilafor enrolls the first patient to test tafoxiparin in certain pregnant women
Karolinska Development’s drug developer Dilafor AB, focused on tafoxiparin for obstetric indications, has enrolled the first subject in its Phase 2b study with tafoxiparin in pregnant women planned for labor induction, Karolinska said Tuesday in a press release.
